Share clinical data and development update for BEAM-302
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Aug 2025
- Due
- 31 Mar 2026
- Delivered
- March 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data from Parts A and B of the Phase 1/2 Trial and Clinical Development Update Expected in Early 2026”
What we found
Evidence strength A What the grades mean
The company announced updated safety and efficacy data for BEAM-302 in March 2026, fulfilling the commitment to share clinical data and a development update by early 2026.
-
A Beam Therapeutics Inc. 8-K filed 2026-05-07
“The updated topline data from BEAM-302 – including robust increases in total AAT and a well-tolerated safety profile – give us high confidence in the 60 mg optimal biological dose” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 10-Q filed 2026-05-07
“In March 2026, we announced updated safety and efficacy data from the trial.” ✓ confirmed on the page
Market reaction: the shares moved -2.6% against the S&P 500 over the three sessions around the disclosure (6 May 2026 to 11 May 2026). What this measures
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Share
- Deliverable
- BEAM-302 clinical data and development update
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-BEAM-003312 · Corrections policy